Boston Scientific (NYSE:BSX) delivered a strong start to 2026, reporting first-quarter net sales of $5.203 billion.
This represents an 11.6% increase on a reported basis and 9.4% growth on an operational and organic basis compared to the same period last year.
The results underscore the company’s sustained momentum in high-growth medtech markets, particularly within its structural heart and electrophysiology segments.
The company reported GAAP net income attributable to Boston Scientific common stockholders of $1.341 billion, or $0.90 per share, a significant increase from the $674 million, or $0.45 per share, recorded in the first quarter of 2025.
On an adjusted basis, earnings per share (EPS) for the period reached $0.80, compared to $0.75 a year ago, reflecting improved operational leverage and a favorable product mix.
Performance during the quarter was bolstered by the continued global rollout of the Farapulse Pulsed Field Ablation (PFA) system and steady gains in the Watchman franchise.
These innovations have allowed Boston Scientific to capture additional market share in the atrial fibrillation and stroke prevention markets.
Additionally, the company's MedSurg segment, which includes endoscopy and urology, showed resilient growth as procedural volumes remained stable across major geographic regions.